Cardioptimus develops a patent-pending embolic deflection device to aid in transcatheter aortic valve replacement. The device would deflect emboli down the descending aorta to prevent neurological dysfunctions such as stroke, enabling doctors to improve patient outcomes during TAVR (transcatheter aortic valve replacement) and cardiac surgery